Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects

Lignende værker

• Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
  af: Dymond, Angela W., et al.
  Udgivet: (2017)
• Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
  af: Hoover, Randall K., et al.
  Udgivet: (2017)
• Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials
  af: Dymond, Angela W., et al.
  Udgivet: (2016)
• Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
  af: Kato, Manabu, et al.
  Udgivet: (2017)
• Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment
  af: Hoover, Randall K., et al.
  Udgivet: (2018)